Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 445-454

  Mulders, Peter ^b   Tso, Cho Lea ^b   Gitlitz, Barbara ^a   Kaboo, Randhir ^b   Hinkel, Andreas ^b   Frand, Stacey ^b   Kiertscher, Sylvia ^a   Roth, Michael D ^a   DeKernion, Jean ^b   Figlin, Robert ^a   Belldegrun, Arie ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL DIVISION; DENDRITIC CELLS; FEASIBILITY STUDIES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; PHENOTYPE;

EID: 0033048533     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J., 65: 5-7, 1996.
2. Ries, L. A. G., Miller, B. A., Hankey, B. F., Kosary, C. L., Harras, A., and Edwards, B. K. (eds.). SEER Cancer Statistics Review 1973-1991: Tables & Graphs, National Cancer Institute. NIH Health Publication No. 94-2789. Bethesda, MD: NIH, 1994.
3. Fyfem, G. A., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 14: 2410-2411, 1996.
4. Piercem W. C., Belldegrun, A., and Figlin, R. A. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin. Oncol., 22: 74-80, 1995.
5. Belldegrun, A., Abi-Ada, A., and Figlin, R. A. Renal cell carcinoma: basic biology and current approaches to therapy. Semin. Oncol., 18: 96-101, 1992.
6. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
7. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
8. Celluzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D. Peptide-pulsed dendritic cells induce antigen-specific, CTL mediated protective tumor immunity. J. Exp. Med., 183: 283-287, 1996.
9. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
10. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA, 92: 8078-8082, 1995.
11. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
12. O'Sullivan, G. C., Corbett, A. R., Shanahan, F., and Collins, J. K. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J. Immunol., 157: 4717-4720, 1996.
13. Young, M. R., Wright, M. A., Lozano, Y., Matthews, J. P., Benefield, J., and Prechel, M. M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Intl. J. Cancer, 67: 333-338, 1996.
14. Gabrilovich, D. I., Corak, J., Ciernek, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
15. Melief, C. J. M. Dendritic cells as specialized antigen-presenting cells. Res. Immunol., 140: 902-907, 1989.
16. Thurnher, M., Radmayr, C., Ramoner, R., Ebner, S., Bock, G., Klocker, H., Romani, N., and Bartsch, G. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer, 68: 1-7, 1996.
17. Bonham, C. A., Lu, L., Banas, R. A., Fontes, P., Rao, A. S., Starzl, T. E., Zeevi, A., and Thomson, A. W. TGF-β 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells. Transplant. Immunol., 4: 186-191, 1996.
18. Chaux, P., Moutet, M., Faivre, J., Martin, F., and Martin, M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab. Invest., 74: 975-983, 1996.
19. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
20. Zied, N. A., and Muller, H. K. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology, 25: 338-343, 1993.
21. Becker, Y. Anticancer role of dendritic cells (DC) in human and experimental cancers: a review. Anticancer Res., 12: 511-520, 1992.
22. Applegate, K. G., Balch, C. M., and Pellis, N. R. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in TILs. Cancer Res., 50: 7153-7158, 1990.
23. Belldegrunm, A., Tso, C-L., Kaboo, R., Pang, S., deKernion, J. B., Pierce, W., and Figlin, R. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma (RCC) receiving tumor-infiltrating lymphocytes (TILs) and interleukin-2 (IL-2) based therapy. J. Immunother., 19: 149-161, 1996.
24. 1ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.
25. Kiertscher, S. M., and Roth, M. D. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukocyte Biol., 59: 208-218, 1996.
26. Konomi, Y., Sekine, T., Takayama, T., Fuji, M., and Tanaka, T. Cytotoxic activity of CD4+ T cells against autologous tumor cells. Jpn. J. Cancer Res., 86: 854-860, 1995.
27. Slingluff, C. L., Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin. Surg. Oncol., 12: 446-453, 1996.
28. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Garcia-Prats, M. D., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 75: 94-103, 1997.
29. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
30. Nair, S. K., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer, 70: 706-715, 1997.
31. Tjoa, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L., and Murphy, G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate, 28: 65-69, 1996.
32. Cohen, P. A., Cohen, P. J., Rosenberg, S. A., and Mule, J. J. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res., 54: 1055-1058, 1994.
33. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
34. Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA, 92: 11810-11813, 1995.
35. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med., 184: 741-746, 1996.
36. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.
37. Zeh, H. J., III, Hurd, S., Storkus, W. J., and Lotze, M. T. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother., 14: 155-161, 1993.
38. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D., and Schuler, G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods, 196: 137-151, 1993.
39. Bender, A., Sapp, M., Schuler, G., Steinman, R. M., and Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods, 196: 121-135, 1996.
40. Fortin, A., Shahum, E., Krzystyniak, K., and Therien, H. M. Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Cell. Immunol., 169: 208-217, 1996.
41. Zhou, F., and Huang, L. Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway. Immunomethods, 4: 229-235, 1994.